Our findings in the present study also confirmed that high levels of CD38+CD8+ T cells are indicative of incomplete tumor response in patients with HCC treated with TACE with or without the administration of PD-1 inhibitors. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.